Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Argenx Se ADR
(NQ:
ARGX
)
463.41
-8.39 (-1.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Argenx Se ADR
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Dow Jones Leads Market Advance As Tesla, Netflix, Taiwan Semiconductor Hit Growth: Weekly Review
July 21, 2023
But all the major indexes are at or near 15-month highs.
Via
Investor's Business Daily
Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade
July 20, 2023
On Thursday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, from 78 to 81.
Via
Investor's Business Daily
The Latest Analyst Ratings for argenx
July 20, 2023
Via
Benzinga
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
July 20, 2023
From
argenx SE
Via
GlobeNewswire
If You Invested $100 In This Stock 5 Years Ago, You Would Have $500 Today
July 18, 2023
Via
Benzinga
Why Argenx Stock Is on Fire Today
July 17, 2023
A major clinical win is boosting the drugmaker's shares today.
Via
The Motley Fool
Why Is Argenx (ARGX) Stock Up 27% Today?
July 17, 2023
Argenx (ARGX) stock is climbing higher on Monday following the release of data from a Phase 1 clinical trial of VYVGART Hytrulo.
Via
InvestorPlace
argenx announces full exercise of underwriters’ option to purchase additional ADSs
July 19, 2023
From
argenx SE
Via
GlobeNewswire
argenx raises $1.1 billion in gross proceeds in a global offering
July 18, 2023
From
argenx SE
Via
GlobeNewswire
Immunovant's FcRn Strategy Gains Momentum: Analysts View ADHERE Study as De-Risking Factor for CIDP Clinical Development
July 18, 2023
Monday, Argenx SE (NASDAQ: ARGX) reported topline results from the ADHERE study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with chronic inflammatory demyelinating...
Via
Benzinga
argenx announces launch of proposed global offering
July 17, 2023
From
argenx SE
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
July 17, 2023
Via
Benzinga
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 17, 2023
Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived...
Via
Benzinga
argenx SE (NASDAQ: ARGX) Leading the Way in Monday Trading Based on Percentage Gain
July 17, 2023
Via
Investor Brand Network
Argenx Catapults 27% To Record High As It Edges Closer To A New Multibillion-Dollar Market
July 17, 2023
Vyvgart is already approved in multiple diseases. But Argenx isn't stopping there.
Via
Investor's Business Daily
You Can't Afford to Miss Monday's 2 Nasdaq Biotech Stock Movers
July 17, 2023
Big gains are afoot even as the markets prepare for a flat open.
Via
The Motley Fool
12 Health Care Stocks Moving In Monday's Pre-Market Session
July 17, 2023
Via
Benzinga
Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket
July 17, 2023
Gainers
Via
Benzinga
Why Is BYND Cannasoft Enterprise (BCAN) Stock Down 46% Today?
July 17, 2023
BYND Cannasoft Enterprise (BCAN) stock is dropping on Monday after the company announced an underwritten stock offering.
Via
InvestorPlace
Why Are Argenx Shares Trading Higher Today?
July 17, 2023
Argenx SE (NASDAQ: ARGX) reported topline results from the ADHERE study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with chronic inflammatory
Via
Benzinga
Why Is Quoin Pharmaceuticals (QNRX) Stock Down 90% Today?
July 17, 2023
Quoin Pharmaceuticals (QNRX) stock is taking a massive beating on Monday as the company prepares for an ADS ratio change.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
July 17, 2023
It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday!
Via
InvestorPlace
Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session
July 17, 2023
U.S. stock futures traded mixed this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
July 17, 2023
From
Zai Lab Limited
Via
GlobeNewswire
argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
July 17, 2023
From
argenx SE
Via
GlobeNewswire
This Emerging Market Could Be the Next Big Thing in Biotech
July 14, 2023
Medicines to treat the many symptoms of long COVID are in high demand already.
Via
The Motley Fool
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration
July 08, 2023
F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic...
Via
Talk Markets
argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
June 30, 2023
From
argenx SE
Via
GlobeNewswire
Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
June 30, 2023
From
Zai Lab Limited
Via
GlobeNewswire
FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
June 27, 2023
The FDA approved UCB SA's (OTC: UCBJF) (OTC: UCBJY) Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.